Vice Chair Research, Professor
University of Kansas Department of Otolaryngology
Kansas City, KS, United States
Dr. Villwock is a Professor of Otolaryngology, a fellowship trained rhinologist & anterior skull base surgeon, the Section Chief of Otolaryngology at the Kansas City Veterans Affairs Medical Center, and the Vice Chair for Innovation for the Department of Otolaryngology at the University of Kansas. She is passionate about accessible innovation to improve patient care. Examples of this include her research, which has led to the creation and patenting of AROMA (Affordable, Rapid, Olfactory Measurement Array). This is a novel objective olfactory test that is significantly more cost effective and designed for real-time integration into a clinical workflow. Using AROMA as a noninvasive biomarkers of dementia and cognitive decline is the focus of her recently awarded $3.8M grant from the NIH. Dr. Villwock has also created the Activities Based Checks (ABCs) of Pain, an infographic-style functional pain scale to improve communication about pain between patients and their care teams while decreasing the cognitive load associated with the completion and interpretation of existing pain surveys. She was selected as a finalist in the NIH National Institute on Aging's inaugural Health Aging Challenge and Entrepreneurial Bootcamp for her work with AROMA. Dr. Villwock subsequently won the Audience Choice Award at the 2023 Alzheimer's Association pitch competition and was a finalist at the AARP AgeTech Collaborative at ViVE2023 Making Aging Easier pitch competition.
Surgeons with Physical Disabilities: Challenges and Opportunities for Inclusion
Sunday, September 29, 2024
9:30 AM – 10:30 AM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Key to a Successful Side Hustle: Balancing the Continued Practice of Medicine With Entrepreneurship
Sunday, September 29, 2024
4:00 PM – 5:00 PM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.